Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Clin Cancer Res. 2018 Sep 6;25(3):899–900. doi: 10.1158/1078-0432.CCR-18-2368

Figure 1: Schema for the investigation of intensified therapy in EGFR-mutant lung cancer harboring poor prognosis genomic biomarkers.

Figure 1:

Genomic biomarkers are not routinely employed to guide therapy in EGFR-mutant NSCLC. Yet there could be a clinical role for such biomarkers in differentiating patients who do well with standard single-agent TKI from those who might benefit from studies of intensified therapy Prospective clinical trials which investigate intensified therapy (such as TKI-based combinations) in cases with unfavorable molecular features could help establish the clinical utility of such biomarkers.